

## Project partners

AIT Austrian Institute of  
Technology GmbH



DLR – Project Manage-  
ment Agency – Health



Institute for Medical  
Technology Assessment



Erasmus School of  
Health Policy (ESHPM)  
of Erasmus University  
of Rotterdam



Syreon Research Institute



The University of Oxford




## Project information

Project acronym: HEcoPerMed  
Starting date: 01.01.2019  
Duration: 36 months

## Contact

E-Mail: [info@hecopermed.eu](mailto:info@hecopermed.eu)  
Visit us on: [hecopermed.eu](http://hecopermed.eu)



## Imprint

Coordinator  
AIT Austrian Institute of Technology;  
Dr. Susanne Giesecke

Publisher  
Deutsches Zentrum für Luft-  
und Raumfahrt e. V. (DLR)  
DLR Project Management Agency  
Linder Höhe  
51147 Köln

Editor  
DLR Project Management Agency

Design  
DLR Project Management Agency  
Print: DLR, Köln  
Bonn, May 2018

Picture credits:  
Cover: ipopba / Gettyimages;  
p. 2: Vijay kumar / Gettyimages



# EcoPerMed

Health Economics for Personalised Medicine

HEcoPerMed aims to identify the best health economic modelling and payment strategies for personalised medicine, in order to differentiate between the promises of personalised medicine and reality and to stimulate the adoption of promising personalised medicine approaches across the EU.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 824997.

**Personalised Medicine** “refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention”.


According to Horizon 2020 and European Council Conclusions on personalised medicine for patients (2015/C 421/03)

## About HEcoPerMed

HEcoPerMed stands for “Healthcare- and pharma-economics in support of the International Consortium for Personalised Medicine – ICPeMed”. The project responds to the demand for economic models that evaluate treatments made possible through innovations in personalised medicine. HEcoPerMed also seeks to identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of such innovations. HEcoPerMed goes beyond current assessment and payment models in order to serve the need of personalised medicine for more comprehensive cost-effectiveness estimates – incorporating patient and societal perspectives – and for sustainable affordability of cutting-edge health innovations.

HEcoPerMed is a Coordination and Support Action (CSA) financed by Horizon 2020.

## The CSA HEcoPerMed: Framework and Environment



### Work packages (WP):

#### 1. Guidance on health economic modelling

- Provide a systematic review of existing model-based economic evaluations of personalised medicine
- Develop guidance on health economic modelling and identify best practices
- Conclude on current estimates of the value of personalised medicine

#### 2. Application of best practice health economic modelling in personalised medicine

- Select three case studies in the area of personalised medicine
- Develop cost-effectiveness and budget impact models by using guidance developed in WP1
- Test and validate the applicability of the developed guidance and suggest adjustments

#### 3. Financing and payment models

- Identify existing financing models and explore the views, concerns, and preferences of stakeholders with regards to designing appropriate financial incentives for personalised medicine
- Establish a set of appropriate financing and payment models for personalised medicine and provide recommendations for their adoption

#### 4. Benefits and challenges for European health care

- Identify the main trends and drivers in personalised medicine
- Apply a condensed foresight approach to tackle the benefits & challenges of personalised medicine for the European social models of health care
- Show options for institutional support for personalised medicine
- Assess the significance of personalised medicine for the citizens

#### 5. Dissemination and communication

- Two scientific workshops will be organised to present and discuss the preliminary outcome
- At stakeholder conference at the end of the project to present and discuss all results & recommendations
- Continuous communication via the webpage & specific publications such as flyer and newsletter

#### 6. Coordination and Management

- Coordination of the project, including risk mitigation; and overall legal and financial management